PHARMACEUTICAL AND DIET FORMULATIONS FOR THE PROPHYLAXIS AND TREATMENT OF GASTROINTESTINAL DISORDERS

Abstract: The present invention refers to pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders.

Description: PHARMACEUTICAL AND DIET FORMULATIONS FOR THE PROPHYLAXIS AND TREATMENT OF GASTROINTESTINAL DISORDERS The present invention referε to pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders. Gastrointestinal disorders, including viral, bacterial and protozoal infections, as well aε chronic inflammatory diseases, or radiation damages, exert a streεε on gaεtrointeεtinal cellε. The main nutrient of mucosal cellε of the gaεtrointeεtinal tract iε giutamine. This amino acid, usually non-essential, becomes "conditionally essential" in pathologies characterized by a giutamine requirement that exceeds the individual's ability to produce sufficient amount of this amino acid. Enteral or parenteral administration of giutamine improves nutritional management and recovery of the patientε (Castel LM et al . (1994) Amino Acids 7, 231-243; Lacey JM, il ore DW (1990) Nutr. Rev. 48 (8), 297-309). Giutamine apart from being the preferred fuel for cells with a rapid proliferation rate such as enterocytes and lymphocytes, iε also a regulator for acid-base balance through the production of ammonia. Enterocytes are the most important cells of small intestine which use giutamine as an energy source (Wu G et al . (1995) Am. J. Physiol. 266, R334-R342; Nagy LE, Kretchmer N (1988) J. Nutr. 118 (2), 189-193). Aε a matter of fact inteεtinal cellε abεorb a remarkable amount of giutamine supplied with the diet and whenever the εupply of this amino ac d is decreased, the amino acid is taken up from the blood. Low levelε of giutamine, experimentally induced in animals, for instance through glutaminase administration, cause intestinal disorders, e.g. chronic diarrhoea, villous atrophy, etc. , (Castel LM et al . (1994) Amino Acids 7, 231-243) thus confirming the importance of giutamine for the intestine. In conclusion, giutamine can be insufficient in certain disorders of the gastrointeεtinal tract. In such situations of giutamine deficiency, the gastrointestinal cells are more vulnerable and therefore more exposed to injury caused, for instance, by infectious agents or ionizing radiations. Conversely injury and stress to gaεtrointestinal cellε can augment their energetic needs, and thus their requirement of giutamine for survival or replacement. Consequently giutamine administration can augment the ability of gastrointestinal cells to withstand injury. In addition, the above mentioned positive effects on gastrointestinal cells due to giutamine administration can be further enhanced by the addition of arginine which acts both on the immune syεtem and the wound-healing rate (Wu G et al . (1995) Am. J. Phyεiol. 266, R334-R342). Carbohydrates are thought to act in εynergy with giutamine, but alone they cannot εubstitute it (Wu G et al . (1995) Am. J. Phyεiol. 266, R334-R342). In εolution giutamine is not completely stable. In particular, during heat sterilization of giutamine solutions, pyrogluta ate and glutamic acid may form. Giutamine containing polypeptides are much more εtable. Upon ingeεtion of εuch polypeptideε, giutamine may be releaεed in the stomach and intestine by proteases. Therefore a sufficient amount of giutamine can be also achieved by administering small or large polypeptides containing giutamine such as for instance L-alanyl-L- glutamine or glycyl-L-glutamine or glycyl-glycyl-L- giutamine. Lactic acid bacteria, particularly lactobacilli, aε well as other bacteria isolated from the gastrointestinal tract of healthy human beings or animals, have long been known to produce a prophylactic and therapeutic effect on gastrointeεtinal infections (Zoppi G. et al . (1982) Eur. J. Pediatrics 139, 18-21). Such bacteria go under the name of eubiotic bacteria. Some bacterial species may compete with pathogenic ones for nutrients and/or attachment siteε on the gastrointestinal mucous membrane. In addition they can favour the return of pH to normal values. For instance, the strain Enterococcus faecium SF 68 (earlier called Streptococcuε faecium SF 68) , originally isolated from pig intestines, has been proven to be effective in clinical studies (Borgia M et al . (1982) Curr. Ther. Reε. 31(2), 265-271; Bellomo G et al . (1980) Curr. Ther. Reε. 28(6), 927-936; Ca arri E et al . (1981) Chemotherapy 27, 466-470; Wunderlich PF et al . (1989) J. Int. Med. Reε. 17, 333-338). Due to a low affinity of this bacterium for the gastrointestinal mucous membrane, a regular administration for a prolonged period iε needed. In contrast, patients treated with bacteria showing good adherence to the mucous membrane, will require less frequent and leεε prolonged adminiεtration to achieve a cure. Bacteria belonging to the Lactobacillus genuε, which are able to adhere to human gastrointeεtinal mucous membranes, and thus competing with pathogenε with similar adhering properties, have been isolated from healthy human beingε and their characteriεtics are disclosed in US Patent No. 4839281, US Patent No. 5032399, and WO Patent Appl. 95/33046. For instance, US patents No. 4839281 and 5032399 disclose the Lactobacillus acidophilus strain ATCC 53103 isolated from adults and characterized by good adhesion properties. The taxonomic classification of the strain was more recently revised and the strain classified aε Lactobacillus casei sbεp. rhamnosuε . In certain countries dietetical products based on thiε strain, commonly called Lactobacillus GG, have reached the market (e.g., Gefilus' R ) fermented milk and Gefiluε' R ' fermented whey drink in Finland). Other εtrainε, with dramatically improved adheεion propertieε, belonging to the genuε Lactobacillus are the εtrainε CNCM 1-1390, CNCM 1-1391, CNCM 1-1392, and CNCM 1-1447. They are diεclosed in WO Patent Applicationε 95/33046. In addition to excellent adhesion propertieε they are characterized by favourable technological propertieε with reεpect to production and conservation. Antibioticε are widely uεed to treat acute infections. The gaεtrointeεtinal flora become impoveriεhed. Lactobacilli administration may be used to restore a well functioning flora. In such caseε it could be uεeful to εelect bacteria which are reεiεtant to antibioticε. Aε a matter of fact, many bacteria εhow an intrinεic reεiεtance to antibioticε. Otherwiεe, antibiotic reεiεtance can be induced by mutagenesis, for example by using agents which speed up the normal mutation rate. Then, the mutated strains are selected by well-known procedures. Alternatively, widely known techniques of genetic engineering can produce bacteria endowed with specific resistance to antibiotics. Some eubiotic bacteria show a bacteriostatic or even bactericidal behaviour toward pathogens. These activities partially result from the production of metabolites, such as lactic acid, acetic acid, and hydrogen peroxide, which make the environment less favourable for the growth of pathogenε. In addition, several lactic acid bacteria are known to produce other substances such as antibioticε and bacteriocins. And obviously theεe bacteria gather special interest. In order to verify whether the simultaneous presence of giutamine could posεibly influence the growth of eubiotic bacteria, in vitro experimentε were performed. Eubiotic strains were incubated at 37°C under 5% C0 2 atmosphere in MRS broth (lactobacilli strains) or BHI broth { Enterococcus faecium) both in the absence and in the presence of 4% giutamine. Bacterial counts were carried out after 12 h, 24 h and 48 h. The results are summarized in Table I. Table I. Bacterial growth in the absence and in the presence of giutamine at different timeε a Strains 12 h 24 h 48 h -Gin +Gln -Gin +Gln -Gin +Gln ATCC 53103 9.1 9.0 9.4 9.3 9.0 9.2 CNCM 1-1447 9.0 8.8 9.0 8.6 9.1 8.9 CNCM 1-1391 9.0 8.9 9.2 9.1 9.5 9.5 Enterococcus faecium . 8.4 8.5 9.5 9.3 9.0 9.4 a Values are expresεed aε log CFU/mL. CFU = Colony Forming Unit. The data indicate that the simultaneous preεence in culture medium of giutamine does not inhibit the growth of bacteria. Similar experimentε were carried out in the presence of bile as well as at different values of pH. Even in these tests the presence of giutamine did not interfere with the growth of the tested bacteria. As part of the present invention, it has now been found that thanks to the combination of therapeutic bacteria and giutamine or giutamine containing polypeptides, highly advanced pharmaceutical products can be manufactured, showing surprisingly favourable therapeutic effects over each components of the combination taken alone. In particular indications were obtained that therapy with eubiotic bacteria accelerates recovery. In pharmaceutical formulations, eubiotic bacteria are usually lyophilized to preserve their stability as disclosed in US Pat. No. 3897307 and in European Patent Appl. EP-A-259739. In some caseε, bacteria lyophilization requireε the uεe of stabilizerε in the aqueous phase to reduce the formation of long ice crystals. Said agents include, for instance, carbohydrates, amino acids, polypeptides, proteins, synthetic polymers and dimethylsulfoxide. US patent 3897307 discloses the preparation of stabilized dried bacterial strains, by adding, before drying, "potentiators", in particular L-ascorbic acid and water- soluble edible salts to the grown culture. Another compound which can be used in this process is trehalose. It has now surprisingly been found that giutamine or polypeptides containing giutamine, in particular in the presence of added carbohydrates, and or other complex mixtures of extracts of animal or vegetal origin, such as, for example, yeast or meat extracts or dry milk, can also be used to stabilize bacteria during lyophilization. Alternatively, during lyophilization bacteria can be stabilized by any usual method known to the skilled technician and stored in the form of a granulate mixture containing the other components of the pharmaceutical product, that's to say giutamine or a derivative thereof preferably together with additives such as arginine or carbohydrates or dry milk and so on. Experimental lyophylization tests, conducted on eubiotic bacteria alone and in the presence of 4% giutamine, or a mixture of giutamine and dry milk, confirmed the above statement. Alternatively, lyophilized bacteria with its additives and giutamine or glutamine-containing polypeptides and its additives be stored in separate sachets to be ingested in synchrony after dissolution or suspension of each of the two components of the pharmaceutical product in water. Presently some bacterial products are lyophilized powders in pharmaceutical capsules. Obviously one particular realization of the present invention envisions the preparation of said bacteria containing capsules which are to be ingested with a drink prepared by dissolving/suspending the other components, giutamine or glutamine-containing polypeptides plus eventual additives such as arginine in water. In this case, the capsules and the sachets containing the amino acids can be packaged together in a single confection assuring a correct single-dose administration of the two different components. EXAMPLE 1 Capsules containing 10 6 -10 1 2 cells of lyophilized Enterococcus faecium SF 68 are packaged in blisters. Sachets, in number equal to capsules, containing a granulate of 3 g of giutamine and 6 g of sucrose are packaged together with the blister. To prepare a single dose, the content of the sachet must be dissolved/suspended in 100-150 mL of water, and then one capsule must be swallowed with help of the prepared solution/suspension, and if necessary, of additional water. EXAMPLE 2 The strain Lactobacillus casei sbsp casei CNCM I- 1391 is grown in MRS broth and the cells harvested by centrifugation. The cells are resuspended at a concentration of approximately 10 10 cells/mL in a filter sterilized solution consisting of 75 g/L of L-glutamine and 150 g/L of sucrose . nd then lyophilized. The resulting lyophilized product is distributed in 9 g doses into sealed sachets. Each dose consists of the content of one sachet dissolved/suspended in 100-150 mL of water. EXAMPLE 3 A formulation similar to that of Example 2 was obtained by using a mixture of lactobacilli strains CNCM 1-1390 and CNCM 1-1447 at a concentration of approximately 10^ cells/mL for each strain. EXAMPLE 4 Sachets containing a granulate consisting of a mixture of 3 g of giutamine, 6 g of sucrose, and at least 10 7 Lactobacillus acidophilus CNCM 1-1447, are prepared. The formulation is administered after diluting the content sachet in 100-150 mL of water. EXAMPLE 5 The formulation of Example 4 was prepared with strain ATCC 53103 at the same concentration. EXAMPLE 6 Sachets containing a granulate consisting of 4 g of glycyl-glycyl-L-glutamine, 3 g of L-arginine and 5 g of glucose and sachets containing at least 10 6 Lactobacillus casei sbsp casei strain CNCM 1-1391, in a dextran stabilized lyophilized form, are prepared. The content of each kind of the sachets should be dissolved/suspended in 100-150 mL of water to obtain the desired therapeutical, prophylactic or dietetical dose. EXAMPLE 7 Two patient volunteers showing already for two days the typical symptoms of traveller's diarrhoea consumed on the third and fourth day, in the morning, at noon and in the evening a capsule containing Streptococcus faecium SF 68 (Bioflorin (R) , Bracco S.p.A., Milan) together with a 3 g dose of giutamine and 6 g sucrose. There was observed a rapid sense of relief and no return of symptoms when after two days the therapy was stopped.

Claims: £ ΔIMS 1. A pharmaceutical or dietetical composition comprising: - at least an intestinal eubiotic bacterial strain, in quantities ranging from IO 6 to IO* 2 cells per dose, preferably from 10^ to 10 11 cells per dose, - giutamine in quantities ranging from 0.5 to 10 g per dose, preferably from 2 to 5 g per dose. 2. A composition according to claim 1, in which giutamine is substituted by a glutamine-containing polypeptide. 3. A composition according to claims 1 or 2, in which the composition further comprises L-arginine in quantities between 0.5 and 10 g, preferably between 2 and 5 g. 4. A composition according to claims 1-3, in which the composition further comprises a simple or complex carbohydrate such as sucrose, glucose or starch in quantities ranging from 0 to 10 g or any other stabilizers commonly used in the pharmaceutical technique. 5. A compoεition according to claims 1 or 2, in which the composition further comprises a mixture of extracts of animal or vegetal origin in quantities between 0.5 and 10 g. 6. A composition according to claims 1-5, in which at least one of the components is lyophilized. 7. A composition according to claim 6, in which stabilizers are added before or after the lyophilization. 8. A composition according to claim 7, in which said stabilizers are selected from giutamine, glutamine- containing polypeptides, amino acids, carbohydrates, including ascorbic acid, trehalose and starch. 9. A composition according to claims 1-5, in which said bacteria are lyophilized. 10. A composition according to claim 9, in which said lyophilized bacteria, stabilized or not, are mixed with a granulate containing the other components. 11. A composition according to claim 9, in which the lyophilized bacteria are separately packaged from the other compounds, the two packages constituting the dose of the pharmaceutical product. 12. A composition according to claim 1, in which said bacteria are lactic acid bacteria. 13. A composition according to claim 12, in which said bacteria are lactobacilli. 14. A composition according to claim 12, in which said bacteria are lactobacilli capable of adhering to the intestinal mucous membrane. 15. A composition according to claim 13, in which said lactobacilli are isolated from the gastrointestinal tract of healthy human beings. 16. A composition according to claim 13, in which said lactobacilli belong to one of the strains CNCM 1-1390, CNCM 1-1391, CNCM 1-1392, CNCM 1-1447, ATCC 53103. 17. A composition according to claim 1, in which said bacteria exert a bactericidal or bacteriostatic action on pathogens. 18. A composition according to claim 1, in which said bacteria are Enterococcus faecium SF 68. 19. A composition according to claim 1, in which said bacteria have been selected for their spontaneous resistance, or have been mutated or genetically engineered to become resistant to one or more antibiotics. 20. Use of intestinal eubiotic bacteria and in combination with giutamine or glutamine-containing polypeptides, for the preparation of pharmaceutical or dietetical compositions for the prophylaxis and/or treatment of gastrointestinal disorders.

Inventors: DE HAEN CHRISTOPH, GOZZINI LUIGIA, DE HAEN, CHRISTOPH, GOZZINI, LUIGIA
Applicants: BRACCO SPA, DIBRA SPA, GOZZINI LUIGIA, HAEN CHRISTOPH DE, BRACCO S.P.A., DE HAEN, CHRISTOPH, DIBRA S.P.A., GOZZINI, LUIGIA
Application year: 1996
Main classification: A61K35
IPC codes: A61K31, A61K35, A61K36, A61K38, A61K47, A61P1